Global Vitamin K2 Market By Product (MK-7, MK-4, By Dosage Form, Capsules/Tablets, Softgels, Liquid, Others), By Source ( Natural, Synthetic), By Indication (Bone Health, Heart Health, Blood Clotting, Others), By Application (Health Supplements, Functional Foods and Beverages), By Distribution Channel (Offline, Pharmacies and Drug Stores, Hypermarkets/Supermarkets, Others, Online) , By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

The Global Vitamin K2 Market size is expected to be worth around USD 678.2 Million by 2034, from USD 212.6 Million in 2024, growing at a CAGR of 12.3% during the forecast period from 2025 to 2034.

The industrial landscape for VitaminK2 concentrates—often formulated as menaquinone-4 (MK-4) or menaquinone-7 (MK-7)—is expanding steadily, driven by emerging health evidence, regulatory recognition, and scalable production processes.

VitaminK2 plays a critical role in bone mineralization and vascular health via γ-carboxylation of osteocalcin and Matrix GLA Protein (MGP). Clinical research highlights its importance in cardiovascular system integrity by preventing arterial calcification. Deficiency studies reveal notable public health implications; for instance, short-stature children in a cohort study showed up to 80.6% prevalence of VK2 deficiency, while over 40% of severely disabled children were deficient, indicating serious clinical outcomes. In adult diets, VK2 is typically suboptimal: only about one-third of the US population meets adequate intake for total vitaminK, only one component of which is K2.

Industrial-scale production has advanced significantly. Fermentation using Bacillus subtilis on substrates such as soybean, sunflower, and mung bean yields MK-7 concentrations exceeding 1000µg/100g in optimized processes. Crude glycerol-based media have been refined to optimize MK‑4 output, demonstrating potential cost-effective bioreactor-scale production.

Regulatory milestones—such as GRAS (Generally Recognized as Safe) designation for VK2 (MK-7) in nutritional beverages by the US FDA in 2020 and EU authorization for food use in 2024—have facilitated product inclusion in mainstream foods and supplements.

Key Takeaways

• Vitamin K2 Market size is expected to be worth around USD 678.2 Million by 2034, from USD 212.6 Million in 2024, growing at a CAGR of 12.3%.
• MK-7 held a dominant market position, capturing more than a 68.9% share of the global Vitamin K2 market.
• Capsules/Tablets held a dominant market position, capturing more than a 47.1% share of the global Vitamin K2 market.
• Natural held a dominant market position, capturing more than a 67.4% share of the global Vitamin K2 market.
• Bone Health held a dominant market position, capturing more than a 51.3% share of the global Vitamin K2 market.
• Health Supplements held a dominant market position, capturing more than a 77.7% share of the global Vitamin K2 market.
• Offline held a dominant market position, capturing more than a 73.2% share of the global Vitamin K2 market.
• North America dominates the Vitamin K2 market, holding a significant market share of 45.6%, translating to approximately USD 97.0 million.

By Product

MK-7 dominates with 68.9% share in 2024 due to its superior bioavailability and longer half-life.

In 2024, MK-7 held a dominant market position, capturing more than a 68.9% share of the global Vitamin K2 market. This strong lead is mainly due to its enhanced bioavailability, longer plasma half-life, and increased consumer preference for daily supplementation formats. Compared to other forms of Vitamin K2, MK-7 remains active in the bloodstream for up to 72 hours, allowing for more efficient calcium metabolism and consistent health benefits, particularly for bone and cardiovascular health.

Its origin through natural fermentation—often from Bacillus subtilis natto—also appeals to clean-label and plant-based product segments. This segment continues to benefit from growing adoption in dietary supplements and functional food formulations. With wider regulatory acceptance and rising demand from North America, Europe, and Japan, MK-7 is expected to maintain its dominant market position through 2025.

By Dosage Form

Capsules/Tablets lead with 47.1% share in 2024 owing to ease of consumption and wide retail availability.

In 2024, Capsules/Tablets held a dominant market position, capturing more than a 47.1% share of the global Vitamin K2 market by dosage form. This leadership can be linked to their practicality, precise dosing, longer shelf life, and broad consumer acceptance. These formats are widely preferred in both retail and online sales channels due to their portability and convenience for daily supplementation.

Capsules and tablets also allow for easy formulation with other essential nutrients like Vitamin D3, calcium, and magnesium—further increasing their popularity among health-conscious consumers. The pharmaceutical and nutraceutical industries continue to favor this format for its low production costs and scalable packaging solutions. As health supplements gain more mainstream traction in 2025, the Capsules/Tablets segment is likely to retain its stronghold in both mature and emerging markets.

By Source

Natural source leads with 67.4% share in 2024 driven by clean-label trends and consumer trust in fermentation-based ingredients.

In 2024, Natural held a dominant market position, capturing more than a 67.4% share of the global Vitamin K2 market by source. The strong preference for naturally derived Vitamin K2—especially MK-7 produced through fermentation using Bacillus subtilis natto—has been driven by growing demand for clean-label, plant-based, and minimally processed supplements. Consumers increasingly associate natural sources with higher bioavailability, safety, and long-term health benefits, especially in bone and heart health support. Natural Vitamin K2 is widely used in dietary supplements, fortified foods, and functional beverages due to its non-synthetic origin and compatibility with organic or vegetarian product lines. By 2025, this segment is expected to maintain its lead as food manufacturers and health brands continue to promote naturally sourced ingredients to meet rising expectations around transparency and sustainability.

By Indication

Bone Health leads with 51.3% share in 2024 as awareness of osteoporosis prevention rises globally.

In 2024, Bone Health held a dominant market position, capturing more than a 51.3% share of the global Vitamin K2 market by indication. This segment’s strength comes from increasing awareness about age-related bone loss, especially among postmenopausal women and the elderly. Vitamin K2, particularly in its MK-7 form, supports calcium binding to the bone matrix by activating osteocalcin, making it a key supplement for maintaining bone density and reducing fracture risk. With osteoporosis affecting millions worldwide, healthcare professionals increasingly recommend Vitamin K2 as part of a preventive strategy alongside calcium and Vitamin D3. Public health campaigns in 2024, particularly in Europe and North America, have further boosted demand for K2-based bone supplements. Going into 2025, the Bone Health segment is expected to maintain momentum as more clinical evidence supports its role in skeletal strength and as consumers continue to invest in proactive aging solutions.

By Application

Health Supplements dominate with 77.7% share in 2024 due to rising preventive wellness trends and daily vitamin routines.

In 2024, Health Supplements held a dominant market position, capturing more than a 77.7% share of the global Vitamin K2 market by application. This segment has surged ahead as consumers increasingly turn to dietary supplements to support long-term health, especially for bone strength and cardiovascular wellness. Vitamin K2 is widely formulated into capsules, tablets, and softgels, often alongside calcium and Vitamin D3, making it a go-to solution in daily nutritional routines.

The ease of integrating K2 into supplement regimens and its strong positioning in preventive healthcare have driven consistent retail growth, especially across North America, Europe, and Asia. Brands have also expanded K2 offerings in targeted supplements for aging populations, active adults, and women’s health. As health literacy improves and proactive wellness becomes a daily priority in 2025, the Health Supplements segment is expected to remain the primary growth engine of the Vitamin K2 industry.

By Distribution Channel

Offline channel leads with 73.2% share in 2024 thanks to strong pharmacy presence and trusted in-store purchases.

In 2024, Offline held a dominant market position, capturing more than a 73.2% share of the global Vitamin K2 market by distribution channel. This segment’s strength is mainly due to the strong presence of health supplement retailers, pharmacies, and supermarket chains that continue to serve as the primary buying points for consumers. Many customers still prefer the in-person experience when purchasing vitamins, seeking advice from pharmacists or retail staff before selecting supplements.

Additionally, offline stores offer better accessibility for older consumers and allow immediate product access without waiting for delivery. In emerging markets, traditional retail continues to dominate due to limited digital penetration. Heading into 2025, the offline channel is expected to stay resilient, especially in regions where healthcare professionals and in-store promotions significantly influence consumer purchase decisions.

Key Market Segments

By Product

• MK-7
• MK-4

By Dosage Form

• Capsules/Tablets
• Softgels
• Liquid
• Others

By Source

• Natural
• Synthetic

By Indication

• Bone Health
• Heart Health
• Blood Clotting
• Others

By Application

• Health Supplements
• Functional Foods and Beverages

By Distribution Channel

• Offline
  • Pharmacies & Drug Stores
  • Hypermarkets/Supermarkets
  • Others
• Online

Drivers

Growing Concern Over Bone Health in Aging Populations

A major driving force behind the Vitamin K2 market is the rising global concern regarding bone health, especially as populations age. In 2024, the United States alone counted nearly 10 million adults aged 50 and above suffering from osteoporosis—a condition marked by weakened bones and a heightened risk of fractures—according to the U.S. Surgeon General. This alarming figure has spurred public health initiatives aimed at reducing fracture risk through preventive nutrition.

Vitamin K2 plays a critical role in bone mineralization by activating the protein osteocalcin, which binds calcium to the bone matrix. Clinical evidence supports this mechanism: postmenopausal women who supplemented with K2 experienced improvements in vertebral bone mineral density and reduced fracture rates over multi year studies. Government and institutional guidelines are increasingly acknowledging this benefit.

For instance, the European Food Safety Authority has recognized that adequate Vitamin K intake supports maintenance of normal bone conditions, while global nutrition recommendations, such as those by the NIH’s Food and Nutrition Board, have set Vitamin K intake targets—specifically 90 µg/day for women and 120 µg/day for men—to ensure bone health across all age groups .

Efforts to integrate Vitamin K2 into public health strategies are also being observed at a national level. In the United States, the 2020–2025 Dietary Guidelines underscore the importance of nutrients, including Vitamin K from fortified foods or supplements, for older adults who may struggle to meet daily targets through diet alone. This policy support has driven increased incorporation of Vitamin K2 into dietary supplements and functional foods, especially formulations targeting bone health.

Restraints

Warfarin Interaction Risks Limit Vitamin K2 Adoption

A significant restraint on Vitamin K2 market growth is its potential interaction with anticoagulant medications, especially warfarin, used by millions worldwide. Warfarin works by inhibiting vitamin K–dependent clotting factors; adding Vitamin K2 can reduce the drug’s effectiveness and destabilize blood-thinning control. Healthcare guidelines are clear—according to the UK’s NHS, “Do not start taking vitamin K supplements while you are taking warfarin without checking with your doctor first”

This caution affects a sizable patient population. In the United States, around 2 million people use warfarin chronically for conditions such as atrial fibrillation and thromboembolism. A moderate interaction exists between Vitamin K₂ and warfarin, meaning frequent blood test monitoring (INR) is required to maintain safe clotting levels . Patients are advised to avoid vitamin K supplements unless their intake is strictly managed, which makes such supplements less appealing or accessible for those on long-term warfarin therapy.

Government and institutional bodies support this guidance. The U.S. FDA and the European Medicines Agency underscore the importance of consistent dietary vitamin K intake for patients on Vitamin K antagonists, while protocols in Australia and Canada require dosage adjustments and monitoring when K-vitamin supplements are introduced or withdrawn. The potential disruption of anticoagulant therapy poses a public health concern and limits market potential in regions with high warfarin use.

For manufacturers and marketers of Vitamin K₂ products, this means careful messaging and packaging are necessary. Labels must include disclaimers advising consumers to consult healthcare providers if they are on blood-thinning medication. Education and engagement with healthcare professionals are critical to avoid contraindications and ensure safe usage guidelines.

Opportunity

Fortification of Staple Foods with Vitamin K2 Opens New Market Avenues

One significant opportunity for the Vitamin K2 market lies in its integration into staple food fortification programs. Leading authorities and public health data indicate that while food fortification has been widely used for vitamins A, D, and iron, Vitamin K supplementation remains largely unexplored except in select cases. A recent study noted that “contribution of fortified foods to vitamin A,D,E, and K intake was minor, except in toddlers”

Organizations like the World Health Organization (WHO) actively recommend large-scale food fortification as a cost-effective method to combat micronutrient deficiencies globally. Fortifying staples such as flour, rice, or edible oil with Vitamin K2 could address suboptimal dietary intake, especially in regions where green leafy vegetables and fermented foods are less common. In many countries, only one-third of adults meet the adequate intake level for total Vitamin K (including K1 and K2), according to the U.S. National Health and Nutrition Examination Survey (NHANES)

A yogurt fortified with just 28µg of MK-7 daily increased blood levels of VitaminK2 from 0.28ng/mL to 1.94ng/mL over three months. This clear demonstration of bioavailability highlights the potential for fortified foods to improve Vitamin K2 status across wider populations. Fortification could particularly benefit toddlers, pregnant women, and the elderly—groups frequently identified as vulnerable.

Trends

Rise of Fermentation-Based Plant Foods Boosts Vitamin K2 Appeal

One of the latest trends shaping the Vitamin K2 market is its increasing association with fermented plant-based foods. Consumers in 2025 are gravitating toward holistic wellness, sustainability, and clean labels—factors fueling demand for K2-rich, fermented options like natto, plant-based yogurts, and kombucha.

These foods not only offer probiotic benefits but also deliver menaquinone naturally, a combination that resonates deeply with health-conscious shoppers. As noted by a recent North American market analysis, the fermented plant-based food segment is projected to grow at over 8% CAGR from 2024 to 2030, reflecting surging demand for nutrient-dense, sustainable product formats

The U.S. FDA’s updated “healthy” nutrient claim definitions—which now emphasize transparency and nutrient content—further support the inclusion of Vitamin K2 in consumable foods. Under these rules, manufacturers have clearer pathways to brand fermented plant-based foods fortified with Vitamin K2 as genuinely “healthy,” heightening consumer trust and aiding market positioning for such products.

Scientific studies lend critical validation: a small-scale intervention showed that adding 28µg of MK 7 via fortified yogurt raised blood levels of Vitamin K2 from 0.28ng/mL to 1.94ng/mL in just three months. Highlighting this level of efficacy links plant-based fermented foods directly to measurable health outcomes—particularly bone and cardiovascular benefits—without resorting to pills or powders. This seamless integration is meaningful to consumers seeking both convenience and quality.

Regional Analysis

North America dominates the Vitamin K2 market, holding a significant market share of 45.6%, translating to approximately USD 97.0 million. This dominance is driven primarily by increasing consumer awareness regarding the health benefits of Vitamin K2, particularly in bone health and cardiovascular care. The robust growth in the dietary supplements industry across the United States and Canada further boosts market demand. Additionally, rising incidences of osteoporosis and cardiovascular disorders have propelled healthcare professionals to advocate for Vitamin K2 supplementation, thereby augmenting regional sales.

The region’s stronghold is supported by the presence of major industry players, innovative product offerings, and proactive marketing strategies that educate consumers on preventive healthcare. Moreover, advanced research and development activities within the nutritional supplements sector in North America consistently lead to enhanced formulations and broader product portfolios, appealing to diverse consumer segments.

Furthermore, North America’s favorable regulatory environment, characterized by clearly defined guidelines from bodies such as the FDA and Health Canada, ensures consumer trust and stimulates consistent market expansion. The trend toward preventive healthcare, coupled with the aging population in North America, significantly contributes to sustained market growth. Ongoing initiatives by supplement manufacturers to collaborate with healthcare providers for promoting Vitamin K2 benefits also solidify market growth.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of MEA

Key Players Analysis

NOW Foods offers a non-GMO, soy-free MK-7 supplement that supports vascular and bone health with a 100µg dosage per capsule, priced at around $21.99 for a 60-count bottle. The brand leverages clean-label fermentation sourcing and positions its product through health-focused messaging. NOW’s consistent presence in both retail and health-food chains, combined with accessible pricing and alternative strength options, solidifies its role as a mainstream provider in the VitaminK7 market.

Life Extension markets both a low-dose MK 7 softgel and a high-potency MK 4 formulation (45 mg), targeting bone density and cardiovascular markers. The low-dose model caters to daily maintenance routines, while the high-dose option mirrors Japanese clinical protocols for osteoporosis. The brand aligns with scientific expertise, third-party verification, and customer trust, enabling it to straddle consumer wellness and therapeutic positioning within the expanding K2 market.

Pharmavite’s Nature Made line provides a USP-verified, pharmacist-recommended MK 7 softgel at 100µg, targeting bone and circulatory benefits. The brand emphasizes quality through third-party testing and strong pharmacy distribution channels, promoting its supplements as reliable, evidence-based products. Nature Made enhances credibility and reach via large-scale manufacturing and mainstream retailing, reinforcing its status as a trusted label in VitaminK2 supplementation.

Top Key Players in the Market

• NOW Foods
• Life Extension
• Pharmavite (Nature Made)
• Nestlé (Garden of Life)
• Bronson
• NatureWise
• Solaray
• Natural Factors
• Source Naturals
• MaryRuth Organics

Recent Developments

NOW Foods, a prominent player in the Vitamin K2 supplement segment, offers two key formulations—MK 4 (100 mcg) and MK-7 (100 mcg)—available in vegan capsules priced at USD 16.99 for 100-count and USD 21.99–34.99 for MK-7 variants in 2024.

NatureWise operates in the VitaminK2 category with a dual-formula softgel—combining 100µg of MK-7 and 500µg of MK-4—positioned to support bone and heart health. In 2024, the flagship 90count bottle was priced at approximately USD 14.99, scaling to USD 32.99 for 360 count bulk packs.

Report Scope